Emerging treatments in the management of bipolar disorder -focus on risperidone long acting injection - Archive ouverte HAL Access content directly
Journal Articles Neuropsychiatric Disease and Treatment Year : 2010

Emerging treatments in the management of bipolar disorder -focus on risperidone long acting injection

(1) , (2)
1
2
Wissam El-Hage

Abstract

Bipolar disorder is a lifelong psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. Risperidone long acting injection (RLAI) as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA) in United States in May 2009. In this review we will consider the aspects of pharma-cology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients' perspective and attitudes to long-acting injections will also be discussed.
Fichier principal
Vignette du fichier
2010_ElHage_NDT-7608.pdf (169.81 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-02524330 , version 1 (30-03-2020)

Identifiers

Cite

Wissam El-Hage, Simon Surguladze. Emerging treatments in the management of bipolar disorder -focus on risperidone long acting injection. Neuropsychiatric Disease and Treatment, 2010, pp.6 - 455. ⟨10.2147/NDT.S7608⟩. ⟨hal-02524330⟩

Collections

INSERM UNIV-TOURS
37 View
46 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More